Intellia Therapeutics (NASDAQ:NTLA) has been assigned a $57.50 price objective by analysts at Chardan Capital in a research note issued to investors on Friday, TipRanks reports. The brokerage currently has a “buy” rating on the stock. Chardan Capital’s price objective suggests a potential upside of 330.71% from the company’s current price.
NTLA has been the topic of a number of other reports. Robert W. Baird initiated coverage on shares of Intellia Therapeutics in a report on Monday, July 8th. They issued an “outperform” rating and a $23.00 price target on the stock. ValuEngine downgraded shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 26th. BidaskClub downgraded shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Friday. Roth Capital initiated coverage on shares of Intellia Therapeutics in a report on Monday, June 10th. They issued a “neutral” rating and a $16.00 price target on the stock. Finally, Zacks Investment Research downgraded shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company. Intellia Therapeutics currently has an average rating of “Hold” and a consensus target price of $25.56.
NTLA remained flat at $$13.35 during mid-day trading on Friday. 203,928 shares of the company’s stock were exchanged, compared to its average volume of 555,608. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.99 and a quick ratio of 7.99. The stock has a market capitalization of $652.06 million, a PE ratio of -6.74 and a beta of 2.71. The business has a 50-day moving average of $14.93 and a 200 day moving average of $15.90. Intellia Therapeutics has a 1 year low of $11.03 and a 1 year high of $28.62.
Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.61) by $0.05. The firm had revenue of $11.10 million for the quarter, compared to the consensus estimate of $7.15 million. Intellia Therapeutics had a negative net margin of 242.65% and a negative return on equity of 33.03%. The business’s revenue for the quarter was up 44.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.52) EPS. On average, equities research analysts expect that Intellia Therapeutics will post -2.29 earnings per share for the current fiscal year.
Several large investors have recently modified their holdings of NTLA. Benjamin Edwards Inc. boosted its holdings in shares of Intellia Therapeutics by 60.9% in the 2nd quarter. Benjamin Edwards Inc. now owns 1,691 shares of the company’s stock worth $28,000 after buying an additional 640 shares during the last quarter. Bank of Montreal Can lifted its holdings in Intellia Therapeutics by 406.5% during the second quarter. Bank of Montreal Can now owns 3,824 shares of the company’s stock valued at $63,000 after purchasing an additional 3,069 shares during the last quarter. Mizuho Securities Co. Ltd. purchased a new stake in Intellia Therapeutics during the second quarter valued at about $64,000. Aperio Group LLC purchased a new stake in Intellia Therapeutics during the second quarter valued at about $83,000. Finally, Resources Investment Advisors Inc. purchased a new stake in Intellia Therapeutics during the first quarter valued at about $92,000. 79.39% of the stock is currently owned by institutional investors.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.